| Previous Close | 46.13 |
| Open | 46.72 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 46.60 - 47.02 |
| 52 Week Range | 39.72 - 48.38 |
| Volume | 649,052 |
| Avg. Volume | 1,386,659 |
| Market Cap | 324.688B |
| Beta (5Y Monthly) | 0.27 |
| PE Ratio (TTM) | 20.77 |
| EPS (TTM) | 2.25 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.22 (2.61%) |
| Ex-Dividend Date | Mar. 18, 2021 |
| 1y Target Est | N/A |
- Zacks
Roche's (RHHBY) BLA for PDS With Ranibizumab Accepted by FDA
The FDA accepts and grants Priority Review to Roche's (RHHBY) application for Port Delivery System with ranibizumab for the treatment of nAMD.
- Business Wire
FDA Accepts Application for Genentech’s Port Delivery System With Ranibizumab (PDS) for Treatment of Wet Age-Related Macular Degeneration (AMD)
SOUTH SAN FRANCISCO, Calif., June 24, 2021--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA), under Priority Review, for Port Delivery System with ranibizumab (PDS) for the treatment of wet, or neovascular, age-related macular degeneration (AMD). Wet AMD is a leading cause of blindness for people aged 60 and over and impacts approximately 1.1 million
- GlobeNewswire
FDA accepts application for Roche’s Port Delivery System with ranibizumab (PDS) for treatment of neovascular or “wet” age-related macular degeneration (nAMD)
If approved, PDS would be the first and only eye implant with continuous drug delivery that offers people living with nAMD an alternative to frequent eye injectionsA pivotal study showed PDS extends time between treatments up to six months for more than 98% of patients and provides vision outcomes equivalent to monthly ranibizumab injectionsThe European Medicines Agency has also validated the PDS Marketing Authorisation Application in nAMD Basel, 24 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY)
